Last edition
News about "atopic dermatitis "
Sanofi, Regeneron Expand Alliance to Develop Four Long-Acting Antibodies
Sanofi and Regeneron expands their antibody collaboration to develop and commercialise four next-generation long-acting antibodies for immune-mediated diseases.
Atopic Dermatitis | 03/10/2026 | By News Bureau | 101
Acrotech Biopharma Launches Adquey for Atopic Dermatitis in US
Acrotech Biopharma launches Adquey ointment in the US for the topical treatment of mild-to-moderate atopic dermatitis.
Atopic Dermatitis | 01/10/2026 | By News Bureau
Organon Canada Expands Nduvra Use to Atopic Dermatitis
Organon Canada expands the use of Nduvra to moderate to severe atopic dermatitis, marking the second approved indication for tapinarof cream in the country.
Atopic Dermatitis | 29/09/2026 | By News Bureau | 144
Aethlon Medical to Merge with North Immunology in All-Stock Deal
Aethlon Medical and North Immunology plan to combine through an all-stock merger, backed by an approximately USD 180 million private placement to advance NOR-101 into clinical development.
Atopic Dermatitis | 18/09/2026 | By News Bureau
ImageneBio Raises USD 30 Million in Private Placement
ImageneBio has raised USD 30 million in private placement led by Coastlands Capital to advance IMG-007 development in alopecia areata and atopic dermatitis.
Atopic Dermatitis | 14/04/2026 | By News Bureau | 130
Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study
Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.
Atopic Dermatitis | 30/03/2026 | By News Bureau | 175
EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis
In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.
Atopic Dermatitis | 17/03/2026 | By Akanki | 141
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
Atopic Dermatitis | 10/03/2026 | By News Bureau | 194
Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Atopic Dermatitis | 16/12/2025 | By News Bureau | 417
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Atopic Dermatitis | 14/10/2025 | By Dineshwori | 1046
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy